PUT RELIEF IN MOTION With PREVICOX®

Rapid absorption
• Reaches peak plasma concentration within 90 minutes after administration

Proven efficacy
• Beneficial for patients with OA, or that have undergone orthopedic surgery or soft-tissue surgery
• By reducing pain and inflammation caused by OA, helps improve lameness and weight bearing
• In a study, yielded improvements in dogs as seen by 96% of owners

Safe when used as recommended

Convenient dosing
• Once-daily dosing, with or without food

Learn more at PREVICOX.com

Important Safety Information
As a class, cyclooxygenase inhibitory NSAIDs may be associated with gastrointestinal, kidney or liver side effects. These are usually mild, but may be serious. Pet owners should discontinue therapy and contact their veterinarian immediately if side effects occur. Evaluation for pre-existing conditions and regular monitoring are recommended for pets on any medication, including PREVICOX. Use with other NSAIDs, corticosteroids or nephrotoxic medication should be avoided. Refer to the enclosed full Prescribing Information for complete details.

Important Reactions Information

<table>
<thead>
<tr>
<th>Animal Category</th>
<th>Pre-Operative</th>
<th>Post-Operative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Firocoxib</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control Group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse Reaction</td>
<td>Number of Dogs</td>
<td>Number of Dogs</td>
</tr>
<tr>
<td>Vomiting</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Bruising at Surgery Site</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Respiratory Arrest</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>SQ Crepitus in Rear Leg and Flank</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Swollen Paw</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Adverse Reactions in the U.S. OA Field Studies

<table>
<thead>
<tr>
<th>Animal Category</th>
<th>Adverse Reaction</th>
<th>Number of Dogs</th>
</tr>
</thead>
<tbody>
<tr>
<td>PREVICOX</td>
<td>Vomiting</td>
<td>58</td>
</tr>
<tr>
<td>PREVICOX</td>
<td>Diarrhea</td>
<td>110</td>
</tr>
<tr>
<td>PREVICOX</td>
<td>Decreased Appetite or Anorexia</td>
<td>33</td>
</tr>
<tr>
<td>PREVICOX</td>
<td>Lethargy</td>
<td>13</td>
</tr>
<tr>
<td>PREVICOX</td>
<td>Pain</td>
<td>21</td>
</tr>
<tr>
<td>PREVICOX</td>
<td>Somnolence</td>
<td>11</td>
</tr>
<tr>
<td>PREVICOX</td>
<td>Hyperactivity</td>
<td>10</td>
</tr>
</tbody>
</table>

*Dogs may have experienced more than one adverse event during the study.
†Sham-dosed (pilled)
‡One dog had hemorrhagic gastroenteritis.

Other adverse reactions based on post-approval experience have been reported. For further details on these adverse reactions, refer to the Post-Approval Experience section of the PI.

Important: If your dog develops any of these adverse reactions, contact your veterinarian immediately.

In case of an emergency: Call your veterinarian at once.

Additional Information

PREVICOX is a registered trademark of Merial. Merial is now part of Boehringer Ingelheim. ©2017 Merial, Inc. Duluth, GA. All rights reserved. PVX14DTCOMPDETAILER-R2 (03/17)
Osteoarthritis (OA) is the #1 cause of chronic pain in dogs

- It has been estimated that 1 out of every 5 dogs over 1 year of age experiences OA pain.

Untreated OA creates a vicious cycle

- Chronic pain can lead to immobility, worsening joint deterioration, and more pain.

Important Safety Information

As a class, cyclooxygenase inhibitory NSAIDs may be associated with gastrointestinal, kidney or liver side effects. These are usually mild, but may be serious. Pet owners should discontinue therapy and contact their veterinarian immediately if side effects occur. Evaluation for pre-existing conditions and regular monitoring are recommended for pets on any medication, including PREVICOX. Use with other NSAIDs, corticosteroids or nephrotoxic medication should be avoided. Refer to the enclosed full Prescribing Information for complete details.
A multimodal approach to relieving pain and inflammation may help liberate dogs from the vicious cycle of untreated OA.

**Medications including NSAIDs**
- Help decrease pain and inflammation

**Weight control**
- A healthy weight can prevent excessive stress on weight-bearing joints

**Nutraceuticals**
- Oral joint-protective nutrients such as omega-3 fatty acid supplements

**Adjunct therapy**
- Treatments, such as cold or heat pad application, massage, or surgery

**Exercise & physical therapy**
- Strengthening the muscles around the joints may improve function. Controlled physical therapy may be needed during OA flareups

**Multimodal Management of OA**

NSAIDs (nonsteroidal anti-inflammatory drugs) are a critical component of treatment

- The goal is to provide rapid and sustained pain relief with minimal side effects

---

**Previcox**

(firocoxib)

PUT RELIEF IN MOTION 3
Relief from OA pain—sustained all day

In a urate crystal (UC)-induced synovitis model

PREVICOX-treated dogs showed no significant lameness relative to baseline

- Four hours after UC injection, dogs receiving PREVICOX showed a nonsignificant increase in lameness score relative to their non-lame baseline measurement\(^4\)
- PREVICOX efficacy persisted 8 hours (which was 18 hours after PREVICOX administration) after UC injection with an average lameness score of just 0.25\(^4\)

No claim of superiority can be made based on these data.

**Study Design:** Positive-control, blinded, four-period cross-over study evaluating the efficacy of PREVICOX vs 3 active comparators in a UC-induced lameness model used to evaluate the efficacy of NSAIDs.\(^4\)
- Healthy mixed-breed dogs (N=8) were allocated to one of four treatment groups and sequences using a randomized block design based on pretreatment body weight
- Each NSAID was administered orally at the approved label dosages, and given at hour 0 (the start of each treatment period)
- Lameness was induced by UC injection of the stifle 10 hours after NSAID administration
- Lameness score and force plate gait analysis (for weight-bearing capacity) were evaluated prior to treatment and at treatment hours 14 and 18 (4 and 8 hours after UC injection, respectively)

Lameness Scoring Scale: 0=no lameness; 1=mild lameness, including toe touch to floor on all of the strides; 2=moderate lameness, including toe touch to floor on all of the strides; 3=severe lameness, including toe touch to floor on ≥50% of the strides; 4=non-weight-bearing lameness, including toe touch to floor on ≤50% of the strides.

PREVICOX maintained weight-bearing capacity of the affected stifle joint

![Bar chart showing weight-bearing capacity comparison](chart.png)

- 84.5% measured PVF as a percentage of baseline, 4 hours after UC injection\(^4\)
- Increased to 94.5%, 8 hours after UC injection\(^4\)

No claim of superiority can be made based on these data.

PVF=peak vertical force.

**Important Safety Information**

As a class, cyclooxygenase inhibitory NSAIDs may be associated with gastrointestinal, kidney or liver side effects. These are usually mild, but may be serious. Pet owners should discontinue therapy and contact their veterinarian immediately if side effects occur. Evaluation for pre-existing conditions and regular monitoring are recommended for pets on any medication, including PREVICOX. Use with other NSAIDs, corticosteroids or nephrotoxic medication should be avoided. Refer to the enclosed full Prescribing Information for complete details.

Improvements both pet owners and veterinarians notice

96% of pet owners saw improvement in their dogs after 30 days, in a field study\textsuperscript{5}

- 60% of owners reported their dogs were “greatly improved”\textsuperscript{5}

Veterinarians saw improvement in 93% of dogs (56% improved >2 grades):\textsuperscript{5}

Signs assessed included:

- Lameness
- Pain on manipulation/palpation
- Range of motion
- Joint swelling

“We saw a difference right away. PREVICOX gave us our playful dog back!”

—Pet owner

Study Design: Prospective, double-blind, randomized, multicenter noninferiority study to compare efficacy and safety of firocoxib (n=110) versus carprofen (n=108) in client-owned dogs with clinical and radiographic evidence of OA.\textsuperscript{5}

- Primary endpoint: Incidence of improvement from baseline in the dog’s overall scores, based on veterinarian assessment of lameness, pain on manipulation/palpation, range of motion, and joint swelling, at study end (approximately day 30). Overall scoring for each dog, based on each clinical sign assessed on a scale of 0 to 3 (0=normal, 3=most severe), was calculated by the following formula: (2x lameness)+(pain on manipulation/palpation)+(range of motion)+(joint swelling)

- Secondary endpoints:
  - Overall incidence of improvement on day 14
  - Individual scores for lameness, pain on manipulation/palpation, range of motion, and swelling of the affected limbs/joints

Owners assessed:

- Improvement in clinical signs associated with OA over the study period
- Daily observation of changes in the dog’s health, behavior, appetite, or thirst
- Grades used for evaluation were greatly improved, moderately improved, mildly improved, and not improved
Rapid absorption after oral administration

- Detected in plasma within 30 minutes\textsuperscript{6}
- Reaches peak plasma levels within 90 minutes\textsuperscript{6}

“It’s as basic as this: I’m sending clients home with PREVICOX and they’re coming back pleased and asking for more.”

—Robert Morrow, DVM
Hollywood Animal Hospital
Allen, Texas

Important Safety Information
As a class, cyclooxygenase inhibitory NSAIDs may be associated with gastrointestinal, kidney or liver side effects. These are usually mild, but may be serious. Pet owners should discontinue therapy and contact their veterinarian immediately if side effects occur. Evaluation for pre-existing conditions and regular monitoring are recommended for pets on any medication, including PREVICOX. Use with other NSAIDs, corticosteroids or nephrotoxic medication should be avoided. Refer to the enclosed full Prescribing Information for complete details.
Put Relief In Motion With PREVICOX®

Significant reduction of postsurgical pain

94% of dogs treated with PREVICOX needed no rescue medication post-soft-tissue surgery⁷

<table>
<thead>
<tr>
<th></th>
<th>Dogs not requiring rescue medication</th>
</tr>
</thead>
<tbody>
<tr>
<td>PREVICOX (n=126)</td>
<td>94%</td>
</tr>
<tr>
<td>Control (n=128)</td>
<td>76% (P=0.006)</td>
</tr>
</tbody>
</table>

- PREVICOX was well tolerated and effective when started approximately 2 hours prior to surgery and continued for 2 additional days

Study Design: Double-blind, negative-control, multicenter field study to compare clinical efficacy and safety of PREVICOX plus standard of care (appropriate to surgical procedures) vs a sham-dosed placebo plus standard of care in client-owned dogs (N=258) of various breeds undergoing abdominal or major external surgeries. In the PREVICOX treatment group, PREVICOX was administered 2 hours prior to surgery and continued for 2 additional days for the control of postoperative pain and inflammation associated with soft-tissue surgery under field conditions.⁷
- Primary endpoint: Treatment success, defined as completion of the study without the need for rescue medication or removal due to adverse reaction
- Secondary endpoint: Evaluation of total pain scores at various time points postsurgery using the Glasgow Composite Pain Scale (GCPS) and the Visual Analog Scale (VAS)
90% of dogs treated with PREVICOX needed no rescue medication post orthopedic surgery

Orthopedic Surgery: Dogs Treated With PREVICOX vs Dogs in Control Group

- PREVICOX was well tolerated and effective when started approximately 2 hours prior to surgery and continued for 2 additional days.

Study Design: Double-blind, multicenter field study to compare clinical efficacy and safety of PREVICOX plus standard of care (appropriate to surgical procedures) vs a sham-dosed placebo plus standard of care in client-owned dogs (N=226) of various breeds undergoing orthopedic procedures. In the PREVICOX treatment group, PREVICOX was administered 2 hours prior to surgery and continued for 2 additional days for the control of postoperative pain and inflammation associated with orthopedic surgery.

- Primary endpoint: Treatment success, defined as completion of the study without the need for rescue medication or removal due to adverse reaction.
- Secondary endpoint: Evaluation of total pain scores at various time points postsurgery using the Glasgow Composite Pain Scale (GCPS) and the Visual Analog Scale (VAS).

Important Safety Information

As a class, cyclooxygenase inhibitory NSAIDs may be associated with gastrointestinal, kidney or liver side effects. These are usually mild, but may be serious. Pet owners should discontinue therapy and contact their veterinarian immediately if side effects occur. Evaluation for pre-existing conditions and regular monitoring are recommended for pets on any medication, including PREVICOX. Use with other NSAIDs, corticosteroids or nephrotoxic medication should be avoided. Refer to the enclosed full Prescribing Information for complete details.
Put Relief In Motion With PREVICOX®

Convenient, once-daily dosing

**Once-daily dosing for dogs weighing 12.5 lbs and up**

- Formulated as barbecue-flavored chewable tablets
- Can be taken with or without food
- Use the same daily dose (5 mg/kg) for all 3 indications

**Practical dosing guide***

<table>
<thead>
<tr>
<th>Dog body weight (lb)</th>
<th>Number of tablets (Daily Dose)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Range</strong></td>
<td>57 mg</td>
</tr>
<tr>
<td>12.5–18</td>
<td>½ tablet</td>
</tr>
<tr>
<td>19–35</td>
<td>1 tablet</td>
</tr>
<tr>
<td>36–71</td>
<td>½ tablet</td>
</tr>
<tr>
<td>72–120</td>
<td>1 tablet</td>
</tr>
<tr>
<td>121–160</td>
<td>1½ tablets</td>
</tr>
<tr>
<td>161–240</td>
<td>2 tablets</td>
</tr>
</tbody>
</table>

*Daily dose is 5 mg/kg. The above is a suggested practical dosing guide.

**Important Safety Information**

As a class, cyclooxygenase inhibitory NSAIDs may be associated with gastrointestinal, kidney or liver side effects. These are usually mild, but may be serious. Pet owners should discontinue therapy and contact their veterinarian immediately if side effects occur. Evaluation for pre-existing conditions and regular monitoring are recommended for pets on any medication, including PREVICOX. Use with other NSAIDs, corticosteroids or nephrotoxic medication should be avoided. Refer to the enclosed full Prescribing Information for complete details.
Safe when used as recommended

PUT RELIEF IN MOTION

Rapid absorption
• Reaches peak plasma concentration within 90 minutes after administration6

Proven efficacy
• Beneficial for patients with OA, or that have undergone orthopedic surgery or soft-tissue surgery7,8
• By reducing pain and inflammation caused by OA, helps improve lameness and weight bearing4
• In a study, yielded improvements in dogs as seen by 96% of owners5

Safe when used as recommended

Convenient dosing
• Once-daily dosing, with or without food9

Learn more at PREVICOX.com

References:

®PREVICOX is a registered trademark of Merial. Merial is now part of Boehringer Ingelheim. ©2017 Merial, Inc. Duluth, GA. All rights reserved. PVX14DTCOMPDETAILER-R2 (03/17)

Important Safety Information
As a class, cyclooxygenase inhibitory NSAIDs may be associated with gastrointestinal, kidney or liver side effects. These are usually mild, but may be serious. Pet owners should discontinue therapy and contact their veterinarian immediately if side effects occur. Evaluation for pre-existing conditions and regular monitoring are recommended for pets on any medication, including PREVICOX. Use with other NSAIDs, corticosteroids or nephrotoxic medication should be avoided. Refer to the enclosed full Prescribing Information for complete details.

Buster’s playmates miss him.
It won’t be for long, because you prescribe PREVICOX.

®PREVICOX

Adverse Reactions Seen in the Soft-tissue Surgery Postoperative Pain Field Studies9

<table>
<thead>
<tr>
<th>Adverse Reactions</th>
<th>Firocoxib Group (n=127)</th>
<th>Control Group† (n=131)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vomiting</td>
<td>5</td>
<td>6</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Bruising at Surgery Site</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Respiratory Arrest</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>SQ Crepitus in Rear Leg and Flank</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Swollen Paw</td>
<td>1</td>
<td>0</td>
</tr>
</tbody>
</table>

Adverse Reactions Seen in the Orthopedic Surgery Postoperative Pain Field Study9

<table>
<thead>
<tr>
<th>Adverse Reactions</th>
<th>Firocoxib Group (n=118)</th>
<th>Control Group† (n=108)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vomiting</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Bruising at Surgery Site</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Inappetence/Decreased Appetite</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Incision Swelling, Redness</td>
<td>9</td>
<td>5</td>
</tr>
<tr>
<td>Dosing incision</td>
<td>2</td>
<td>0</td>
</tr>
</tbody>
</table>

* Dogs may have experienced more than one adverse event during the study.
† Sham-dosed (pilled)
‡ One dog had hemorrhagic gastroenteritis.

Other adverse reactions based on post-approval experience have been reported. For further details on these adverse reactions, refer to the Post-Approval Experience section of the PI.
PUT RELIEF IN MOTION

Rapid absorption
• Reaches peak plasma concentration within 90 minutes after administration6

Proven efficacy
• Beneficial for patients with OA, or that have undergone orthopedic surgery or soft-tissue surgery8
• By reducing pain and inflammation caused by OA, helps improve lameness and weight bearing4
• In a study, yielded improvements in dogs as seen by 96% of owners5

Safe when used as recommended

Convenient dosing
• Once-daily dosing, with or without food9

Learn more at PREVICOX.com

Important Safety Information
As a class, cyclooxygenase inhibitory NSAIDs may be associated with gastrointestinal, kidney or liver side effects. These are usually mild, but may be serious. Pet owners should discontinue therapy and contact their veterinarian immediately if side effects occur. Evaluation for pre-existing conditions and regular monitoring are recommended for pets on any medication, including PREVICOX. Use with other NSAIDs, corticosteroids or nephrotoxic medication should be avoided. Refer to the enclosed full Prescribing Information for complete details.

References:

®PREVICOX is a registered trademark of Merial. Merial is now part of Boehringer Ingelheim. ©2017 Merial, Inc. Duluth, GA. All rights reserved. PVX14DTCOMPDETAILER-R2 (03/17)

Important Safety Information

As a class, cyclooxygenase inhibitory NSAIDs may be associated with gastrointestinal, kidney or liver side effects. These are usually mild, but may be serious. Pet owners should discontinue therapy and contact their veterinarian immediately if side effects occur. Evaluation for pre-existing conditions and regular monitoring are recommended for pets on any medication, including PREVICOX. Use with other NSAIDs, corticosteroids or nephrotoxic medication should be avoided. Refer to the enclosed full Prescribing Information for complete details.

Adverse Reactions Seen in the Soft-tissue Surgery Postoperative Pain Field Studies9

<table>
<thead>
<tr>
<th>Adverse Reactions*Firocoxib Group (n=127)</th>
<th>Control Group† (n=131)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vomiting</td>
<td>56</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>11</td>
</tr>
<tr>
<td>Bruising at Surgery Site</td>
<td>11</td>
</tr>
<tr>
<td>Respiratory Arrest</td>
<td>10</td>
</tr>
<tr>
<td>SQ Crepitus in Rear Leg and Flank</td>
<td>10</td>
</tr>
<tr>
<td>Swollen Paw</td>
<td>10</td>
</tr>
</tbody>
</table>

Adverse Reactions Seen in the Orthopedic Surgery Postoperative Pain Field Study9

<table>
<thead>
<tr>
<th>Adverse Reactions*Firocoxib Group (n=118)</th>
<th>Control Group† (n=108)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vomiting</td>
<td>10</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>2‡1</td>
</tr>
<tr>
<td>Bruising at Surgery Site</td>
<td>23</td>
</tr>
<tr>
<td>Inappetence/Decreased Appetite</td>
<td>12</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>01</td>
</tr>
<tr>
<td>Incision Swelling, Redness</td>
<td>95</td>
</tr>
<tr>
<td>Oozing Incision</td>
<td>20</td>
</tr>
</tbody>
</table>

Adverse Reactions Seen in U.S. OA Field Studies9

<table>
<thead>
<tr>
<th>Adverse Reactions*PREVICOX (n=128)</th>
<th>Active Control (n=121)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vomiting</td>
<td>58</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>110</td>
</tr>
<tr>
<td>Decreased Appetite or Anorexia</td>
<td>33</td>
</tr>
<tr>
<td>Lethargy</td>
<td>13</td>
</tr>
<tr>
<td>Pain</td>
<td>21</td>
</tr>
<tr>
<td>Somnolence</td>
<td>11</td>
</tr>
<tr>
<td>Hyperactivity</td>
<td>10</td>
</tr>
</tbody>
</table>

*Dogs may have experienced more than one adverse event during the study.
†Sham-dosed (pilled)
‡One dog had hemorrhagic gastroenteritis.

Other adverse reactions based on post-approval experience have been reported. For further details on these adverse reactions, refer to the Post-Approval Experience section of the PI.